Novel Gd-loaded silicon nanohybrid: a potential epidermal growth factor receptor expressing cancer cell targeting magnetic resonance imaging contrast agent
Files
(Published version)
Date
2017
Authors
Sinha, S.
Tong, W.Y.
Williamson, N.H.
McInnes, S.J.P.
Puttick, S.
Cifuentes Rius, A.
Bhardwaj, R.
Plush, S.E.
Voelcker, N.H.
Editors
Advisors
Journal Title
Journal ISSN
Volume Title
Type:
Journal article
Citation
ACS applied materials & interfaces, 2017; 9(49):42601-42611
Statement of Responsibility
Conference Name
Abstract
Continuing our research efforts in developing mesoporous silicon nanoparticle-based biomaterials for cancer therapy, we employed here porous silicon nanoparticles as a nanocarrier to deliver contrast agents to diseased cells. Nanoconfinement of small molecule Gd-chelates (L1-Gd) enhanced the T 1 contrast dramatically compared to distinct Gd-chelate (L1-Gd) by virtue of its slow tumbling rate, increased number of bound water molecules, and their occupancy time. The newly synthesized Gd-chelate (L1-Gd) was covalently grafted on silicon nanostructures and conjugated to an antibody specific for epidermal growth factor receptor (EGFR) via a hydrazone linkage. The salient feature of this nanosized contrast agent is the capability of EGFR targeted delivery to cancer cells. Mesoporous silicon nanoparticles were chosen as the nanocarrier because of their high porosity, high surface area, and excellent biodegradability. This type of nanosized contrast agent also performs well in high magnetic fields.
School/Discipline
Dissertation Note
Provenance
Description
Data source: Supporting information, http://pubs.acs.org/doi/abs/10.1021/acsami.7b14538
Access Status
Rights
Copyright 2017 American Chemical Society
Access Condition Notes: Accepted manuscript available after 1 January 2019